Back to search

Article

<em>FLT3</em>-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for <em>FLT3</em> Inhibitor-Based Therapies

2026-07-17

Abstract excerpt

Fms related receptor tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations occur in approximately 20–25% of patients with acute myeloid leukemia (AML) and are associated with increased relapse risk and inferior survival outcomes. Although measurable residual disease (MRD) has become a key prognostic tool for guiding post-remission treatment decisions, FLT3-ITD was historically considered a suboptimal...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
dfaf8e50-2b55-588f-81f4-030cf4b759a5
DOI
10.20944/preprints202607.1293.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
<em>FLT3</em>-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for <em>FLT3</em> Inhibitor-Based TherapiesDOI 10.20944/preprints202607.1293.v1
Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.Semantic proximity
Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.Semantic proximity
Deep Sequencing of FLT3-ITD Enables Response Evaluation and Post-Treatment Monitoring in Childhood AML: An Exploratory Study.Semantic proximity
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutationsSemantic proximity
Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid LeukemiaSemantic proximity
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity
FLT3 mutations as diagnostic and prognostic biomarkers in acute myeloid leukemia.Semantic proximity
Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.Semantic proximity
Clonal Dynamics and Relapse Risk Revealed by High-Sensitivity FLT3-Internal Tandem Duplication Detection in Acute Myeloid Leukemia.Semantic proximity
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.Semantic proximity
Minimal residual disease in acute myelogenous leukemia.Semantic proximity
Peritransplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD-mutated acute myeloid leukemia.Semantic proximity
Select a neighboring publication to make it the new centre.